A key mediator of this effect was IL-5: its increase following Th2 therapy correlated with tumor inhibition and eosinophil infiltration, although recombinant IL-5 alone induced a milder response compared to full Th2-cell administration [70]. Here, IL5 is linked to neoplasm.